128 related articles for article (PubMed ID: 9298937)
1. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge.
Hermans IF; Daish A; Moroni-Rawson P; Ronchese F
Cancer Immunol Immunother; 1997 Aug; 44(6):341-7. PubMed ID: 9298937
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
[TBL] [Abstract][Full Text] [Related]
4. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
5. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
6. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors.
Garrigan K; Moroni-Rawson P; McMurray C; Hermans I; Abernethy N; Watson J; Ronchese F
Blood; 1996 Nov; 88(9):3508-12. PubMed ID: 8896417
[TBL] [Abstract][Full Text] [Related]
7. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
Paglia P; Chiodoni C; Rodolfo M; Colombo MP
J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
Yang S; Darrow TL; Vervaert CE; Seigler HF
Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells efficiently induce protective antiviral immunity.
Ludewig B; Ehl S; Karrer U; Odermatt B; Hengartner H; Zinkernagel RM
J Virol; 1998 May; 72(5):3812-8. PubMed ID: 9557664
[TBL] [Abstract][Full Text] [Related]
10. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CTL reactivity in the spleen and draining lymph nodes after immunization with peptides pulsed on dendritic cells or mixed with Freund's incomplete adjuvant.
Wang MJ; Nissen MH; Buus S; Röpke C; Claësson MH
Immunol Lett; 2003 Nov; 90(1):13-8. PubMed ID: 14611902
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells.
Stober D; Trobonjaca Z; Reimann J; Schirmbeck R
Eur J Immunol; 2002 Apr; 32(4):1099-108. PubMed ID: 11920577
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
[TBL] [Abstract][Full Text] [Related]
15. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.
Takahashi H; Nakagawa Y; Yokomuro K; Berzofsky JA
Int Immunol; 1993 Aug; 5(8):849-57. PubMed ID: 8398980
[TBL] [Abstract][Full Text] [Related]
16. The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapy.
Woo SC; Kim GY; Lee CM; Moon DO; Kim HK; Lee TH; Moon YS; Park NC; Yoon MS; Lee KS; Park YM
Cancer Biol Ther; 2005 Dec; 4(12):1331-5. PubMed ID: 16322691
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
[TBL] [Abstract][Full Text] [Related]
18. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
Met O; Wang M; Pedersen AE; Nissen MH; Buus S; Claesson MH
Cancer Lett; 2006 Jan; 231(2):247-56. PubMed ID: 16399226
[TBL] [Abstract][Full Text] [Related]
19. Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen.
Ozawa Y; Suda T; Nagata T; Hashimoto D; Nakamura Y; Enomoto N; Inui N; Koide Y; Nakamura H; Chida K
Am J Respir Cell Mol Biol; 2009 Oct; 41(4):440-8. PubMed ID: 19202004
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
Tüting T; DeLeo AB; Lotze MT; Storkus WJ
Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
